title: [Taperingstrips for paroxetine and venlafaxine].
abstract: BACKGROUND
  Tapering strips can be used for the gradual reduction of the dose of certain types of drugs such as antidepressants and benzodiazepines. The strips contain a slightly lower dose on each consecutive day. This prevents the withdrawal symptoms still experienced by too many patients and lowers the risk of relapse.
  
  
  OBJECTIVE
  To make tapering strips of antidepressant drugs available for patients in need of a tapering-off procedure.
  
  
  METHODS
  The Consensusgroup Tapering studied the literature and consulted with experts to find out whether the plan to make tapering strips of paroxetine and venlafaxine available for patients is feasible.
  
  
  RESULTS
  The Cinderella Therapeutic Foundation (www.cinderella-tx.org), a not-for-profit organisation which aims to give patients access to orphan drugs and treatments, wants to make tapering strips of paroxetine and venlafaxine available since these are the two antidepressants that cause the most problems. The process of producing, packaging and checking the tapering doses is <span class="abbreviation">iso</span>-certified; each strip is provided with a bar-code and can be followed and traced. Therefore the strips will conform to current safety regulations.In view of the large number of patients taking paroxetine and venlafaxine there is likely to be a considerable demand for tapering strips.
  
  
  CONCLUSIONS
  From a financial, marketing and practical point of view, the introduction of tapering strips is feasable. Patients will derive considerable benefits. The paroxetine strips will be produced first and are expected to be available from December 2013.
authors.forename: P C
authors.initials: PC
authors.lastname: Groot
mesh_terms: D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D003511:Cyclohexanols / Q000008:administration & dosage* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D006801:Humans; D017374:Paroxetine / Q000008:administration & dosage* / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control; D000069470:Venlafaxine Hydrochloride
chemical_list: D000928:Antidepressive Agents; D003511:Cyclohexanols; D017374:Paroxetine; D000069470:Venlafaxine Hydrochloride